Evaluation of Hypoallergenicity of a New Extensively Hydrolyzed Formula

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

83 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-04-30

Study Completion Date

2017-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Infants/children with cow's milk allergy will take part in 2 double-blinded placebo-controlled food challenges (DBPCFC) of 2 extensively hydrolyzed formulas in random order. If both food challenges are passed, subjects will be asked to consume the Test formula in an at-home open challenge for 7 days.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Hypoallergenicity Evaluation of a New Extensively Hydrolyzed Formula

NCT03236207

Cow Milk Allergy

COMPLETED NA

Infant Formula in Infants and Children With Cow's Milk Allergy

NCT06456541

Cow's Milk Allergy

RECRUITING NA

Extensively Hydrolyzed Infant Formula in Infants and Children With Cow's Milk Allergy

NCT04910373

Cow's Milk Allergy

TERMINATED NA

Extensively Hydrolyzed Formula: Hypoallergenicity

NCT01278446

Food Hypersensitivity

COMPLETED NA

Formula for Children With Cow's Milk Allergy

NCT02317952

Milk Allergy

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cow's Milk Allergy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

OTHER

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Test then Control

Subjects will perform a DBPCFC with the Test formula followed by the Control formula

Group Type ACTIVE_COMPARATOR

Test extensively hydrolyzed formula

Intervention Type OTHER

extensively hydrolyzed formula made with a new enzyme

Control extensively hydrolyzed formula

Intervention Type OTHER

commercially available extensively hydrolyzed formula

Control then Test

Subjects will perform a DBPCFC with the Control formula followed by the Test formula

Group Type ACTIVE_COMPARATOR

Test extensively hydrolyzed formula

Intervention Type OTHER

extensively hydrolyzed formula made with a new enzyme

Control extensively hydrolyzed formula

Intervention Type OTHER

commercially available extensively hydrolyzed formula

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Test extensively hydrolyzed formula

extensively hydrolyzed formula made with a new enzyme

Intervention Type OTHER

Control extensively hydrolyzed formula

commercially available extensively hydrolyzed formula

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Born at term (\>36 weeks gestation)
* 2 months to \<4 years of age at enrollment
* Documented CMA within 6 months prior to enrollment
* Otherwise healthy
* Having obtained his/her legal representative's informed consent

Exclusion Criteria

* Children consuming mother's milk at the time of inclusion and during the trial
* Any chromosomal or major congenital anomalies
* Chronic medical diseases (ie seizure disorders, chronic lung disease, heart problems (heart murmurs okay))
* Immunodeficiency
* Receiving free amino acid formula
* Subject who in the Investigator's assessment cannot be expected to adhere to the study protocol
* Currently participating in another clinical trial.

Minimum Eligible Age

2 Months

Maximum Eligible Age

4 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No